Literature DB >> 15995954

Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model.

Alessandra Bragonzi1, Dieter Worlitzsch, Gerald B Pier, Petra Timpert, Martina Ulrich, Morten Hentzer, Jens Bo Andersen, Michael Givskov, Massimo Conese, Gerd Doring.   

Abstract

BACKGROUND: In patients with cystic fibrosis (CF), lung infection with mucoid Pseudomonas aeruginosa strains overexpressing the exopolysaccaride alginate is preceded by colonization with nonmucoid strains. We investigated the kinetics, impact of environmental signals, and genetics of P. aeruginosa alginate expression in a mouse model and in patients with CF.
METHODS: Using indirect immunofluorescence, microarray technology and real-time reverse-transcription polymerase chain reaction, we assessed alginate gene expression during aerobic and anaerobic growth of the nonmucoid strain PAO1 in vitro, in a mouse lung-infection model and in sputum specimens from patients with CF infected with nonmucoid or mucoid P. aeruginosa strains.
RESULTS: Anaerobic conditions increased the transcription of alginate genes in vitro and in murine lungs within 24 h. Alginate production by PAO1 in murine lungs and by nonmucoid P. aeruginosa strains in patients with CF was reversible after in vitro culture under aerobic conditions. A subpopulation of P. aeruginosa clones revealing stable alginate production was detected in murine lungs 2 weeks after infection.
CONCLUSIONS: Anaerobiosis and lung infection rapidly induce alginate production by gene regulation in nonmucoid P. aeruginosa. This trait may contribute to early persistence, leading to chronic P. aeruginosa infection once stable mucoid strains are generated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15995954      PMCID: PMC1317300          DOI: 10.1086/431516

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

2.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

3.  A rat model of chronic respiratory infection with Pseudomonas aeruginosa.

Authors:  H A Cash; D E Woods; B McCullough; W G Johanson; J A Bass
Journal:  Am Rev Respir Dis       Date:  1979-03

4.  Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains.

Authors:  Gerald B Pier; Debra Boyer; Michael Preston; Fadie T Coleman; Nicolas Llosa; Simone Mueschenborn-Koglin; Christian Theilacker; Hannah Goldenberg; Jeffrey Uchin; Gregory P Priebe; Martha Grout; Marshall Posner; Lisa Cavacini
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

5.  Alginate production by clinical nonmucoid Pseudomonas aeruginosa strains.

Authors:  E D Anastassiou; A C Mintzas; C Kounavis; G Dimitracopoulos
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

6.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

7.  A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia.

Authors:  J R Starke; M S Edwards; C Langston; C J Baker
Journal:  Pediatr Res       Date:  1987-12       Impact factor: 3.756

8.  Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients.

Authors:  D W Martin; M J Schurr; M H Mudd; J R Govan; B W Holloway; V Deretic
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis.

Authors:  J Lam; R Chan; K Lam; J W Costerton
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

10.  Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  G B Pier; D Desjardins; T Aguilar; M Barnard; D P Speert
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

View more
  62 in total

1.  Vanadate and triclosan synergistically induce alginate production by Pseudomonas aeruginosa strain PAO1.

Authors:  F Heath Damron; Michael R Davis; T Ryan Withers; Robert K Ernst; Joanna B Goldberg; Guangli Yu; Hongwei D Yu
Journal:  Mol Microbiol       Date:  2011-06-16       Impact factor: 3.501

2.  Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections.

Authors:  Ashley E Warren; Carla M Boulianne-Larsen; Christine B Chandler; Kami Chiotti; Evgueny Kroll; Scott R Miller; Francois Taddei; Isabelle Sermet-Gaudelus; Agnes Ferroni; Kathleen McInnerney; Michael J Franklin; Frank Rosenzweig
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

3.  Long term chronic Pseudomonas aeruginosa airway infection in mice.

Authors:  Marcella Facchini; Ida De Fino; Camilla Riva; Alessandra Bragonzi
Journal:  J Vis Exp       Date:  2014-03-17       Impact factor: 1.355

4.  Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model.

Authors:  Stephanie DeLeon; Allie Clinton; Haley Fowler; Jake Everett; Alexander R Horswill; Kendra P Rumbaugh
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

5.  Surfactant protein A2 (SP-A2) variants expressed in CHO cells stimulate phagocytosis of Pseudomonas aeruginosa more than do SP-A1 variants.

Authors:  Anatoly N Mikerov; Guirong Wang; Todd M Umstead; Mario Zacharatos; Neal J Thomas; David S Phelps; Joanna Floros
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 6.  Regulation of bacterial virulence gene expression by cell envelope stress responses.

Authors:  Josué Flores-Kim; Andrew J Darwin
Journal:  Virulence       Date:  2014       Impact factor: 5.882

7.  Pseudomonas aeruginosa AlgR represses the Rhl quorum-sensing system in a biofilm-specific manner.

Authors:  Lisa A Morici; Alexander J Carterson; Victoria E Wagner; Anders Frisk; Jill R Schurr; Kerstin Höner zu Bentrup; Daniel J Hassett; Barbara H Iglewski; Karin Sauer; Michael J Schurr
Journal:  J Bacteriol       Date:  2007-08-31       Impact factor: 3.490

8.  Regulated proteolysis controls mucoid conversion in Pseudomonas aeruginosa.

Authors:  Dongru Qiu; Vonya M Eisinger; Donald W Rowen; Hongwei D Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

9.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

10.  Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis.

Authors:  Claus Moser; Maria Van Gennip; Thomas Bjarnsholt; Peter Østrup Jensen; Baoleri Lee; Hans Petter Hougen; Henrik Calum; Oana Ciofu; Michael Givskov; Søren Molin; Niels Høiby
Journal:  APMIS       Date:  2009-02       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.